Facial Vitiligo Area Severity Index

NEW ORLEANS — Povorcitinib was associated with substantial repigmentation in patients with extensive nonsegmental vitiligo, according to a study presented at the American Academy of Dermatology Annual Meeting.

Ritlecitinib significantly out-performed placebo across various doses in safety and efficacy for the treatment of nonsegmental vitiligo, according to a clinical trial.

Among patients with vitiligo, treatment with ruxolitinib cream resulted in substantial improvements in total-body repigmentation at week 52 assessed by a 50% or more improvement from baseline in the total vitiligo area severity index, in a phase 2 study building upon previous data, according to data presented at European Academy of Dermatology and Venereology Congress.